{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:39:27Z","timestamp":1771889967314,"version":"3.50.1"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T00:00:00Z","timestamp":1595289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA018151"],"award-info":[{"award-number":["DA018151"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"DOI":"10.3389\/fnins.2020.00765","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:53:41Z","timestamp":1595318021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain"],"prefix":"10.3389","volume":"14","author":[{"given":"Kelly F.","family":"Paton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Biggerstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Kaska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel S.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne C.","family":"La Flamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwyn M.","family":"Kivell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-1879","article-title":"Nalfurafine suppresses pruritogen- and touch-evoked scratching behavior in models of acute and chronic itch in mice.","volume":"95","author":"Akiyama","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/jpet.106.101998","article-title":"Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.","volume":"318","author":"Ansonoff","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00109-011-0752-4","article-title":"Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.","volume":"89","author":"Aviello","year":"2011","journal-title":"J. Mol. Med."},{"key":"B4","first-page":"489","article-title":"Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats.","volume":"264","author":"Bals-Kubik","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.bmc.2008.12.012","article-title":"Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.","volume":"17","author":"Beguin","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"B6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/rheumatology\/kei156","article-title":"Anti-inflammatory effects of contralateral administration of the kappa-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis.","volume":"45","author":"Bileviciute-Ljungar","year":"2006","journal-title":"Rheumatology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/00000542-200106000-00018","article-title":"Analgesic and antiinflammatory effects of two novel kappa-opioid peptides.","volume":"94","author":"Binder","year":"2001","journal-title":"Anesthesiology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1476-5381.2009.00230.x","article-title":"Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.","volume":"157","author":"Braida","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0014-2999(86)90051-8","article-title":"Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice.","volume":"126","author":"Broekkamp","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","article-title":"Kinase cascades and ligand-directed signaling at the kappa opioid receptor.","volume":"210","author":"Bruchas","year":"2010","journal-title":"Psychopharmacology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/jpet.108.145342","article-title":"Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid.","volume":"328","author":"Butelman","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/00000542-200002000-00029","article-title":"Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.","volume":"92","author":"Celerier","year":"2000","journal-title":"Anesthesiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1124\/jpet.103.059394","article-title":"Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.","volume":"308","author":"Chavkin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.drugalcdep.2005.05.009","article-title":"Major increases in opioid analgesic abuse in the United States: concerns and strategies.","volume":"81","author":"Compton","year":"2006","journal-title":"Drug Alcohol Depend."},{"key":"B16","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.1021\/acs.jmedchem.6b01235","article-title":"Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: identification of a Potent and Centrally Acting mu Opioid Analgesic with Reduced Abuse Liability.","volume":"59","author":"Crowley","year":"2016","journal-title":"J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3791\/2609","article-title":"Measuring motor coordination in mice.","volume":"75","author":"Deacon","year":"2013","journal-title":"J. Vis. Exp."},{"key":"B18","first-page":"1067","article-title":"Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.","volume":"244","author":"Di Chiara","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ejphar.2015.05.054","article-title":"Intrinsic relative activities of kappa opioid agonists in activating Galpha proteins and internalizing receptor: differences between human and mouse receptors.","volume":"761","author":"DiMattio","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats.","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","article-title":"Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: toward in Vitro Models of in Vivo Responses.","volume":"10","author":"Dunn","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ijnp\/pyy034","article-title":"Structurally Related Kappa opioid receptor agonists with substantial differential signaling bias: neuroendocrine and behavioral effects in C57BL6 Mice.","volume":"21","author":"Dunn","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.","volume":"35","author":"Ehrich","year":"2015","journal-title":"J. Neurosci."},{"key":"B24","first-page":"30","article-title":"Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo.","volume":"316","author":"Endoh","year":"1992","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1007\/s00213-017-4637-2","article-title":"The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and beta-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.","volume":"234","author":"Ewald","year":"2017","journal-title":"Psychopharmacology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/00008877-200512000-00005","article-title":"Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.","volume":"16","author":"Fantegrossi","year":"2005","journal-title":"Behav. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/ibd.21873","article-title":"Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors.","volume":"18","author":"Fichna","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"B28","first-page":"483","article-title":"Bremazocine - an opiate that induces sedation and analgesia without respiratory depression.","volume":"62","author":"Freye","year":"1983","journal-title":"Anesth. Analg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/j.1742-7843.2008.00306.x","article-title":"Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.","volume":"103","author":"Gallantine","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017.","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-8-60","article-title":"Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection.","volume":"8","author":"Guida","year":"2012","journal-title":"Mol. Pain"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aar4309","article-title":"G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons.","volume":"11","author":"Ho","year":"2018","journal-title":"Sci. Signal."},{"key":"B34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejphar.2006.06.077","article-title":"The antinociceptive effect of salvinorin A in mice.","volume":"545","author":"John","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine*.","author":"Kaski","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neulet.2013.07.040","article-title":"Pharmacokinetic evidence for the long-lasting effect of nor-binaltorphimine, a potent kappa opioid receptor antagonist, in mice.","volume":"552","author":"Kishioka","year":"2013","journal-title":"Neurosci. Lett."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23102602","article-title":"Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.","volume":"23","author":"Kivell","year":"2018","journal-title":"Molecules"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.peptides.2004.05.005","article-title":"Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice.","volume":"25","author":"Kudryavtseva","year":"2004","journal-title":"Peptides"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-017-4758-7","article-title":"Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain\/itch-stimulated and pain\/itch-depressed behaviors in male rats.","volume":"235","author":"Lazenka","year":"2018","journal-title":"Psychopharmacology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion.","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.102.046433","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.","volume":"305","author":"Mague","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B43","author":"Mathew","year":"2019","journal-title":"Exploring the side effect profile of 16-Ethynyl Salvinorin A. Master of Biomedical Science."},{"key":"B44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.pbb.2005.12.011","article-title":"Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.","volume":"83","author":"McCurdy","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00407","article-title":"A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists.","volume":"10","author":"Mores","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/bf00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning.","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/pr.118.017210","article-title":"Core Outcome Measures in Preclinical Assessment of Candidate Analgesics.","volume":"71","author":"Negus","year":"2019","journal-title":"Pharmacol. Rev."},{"key":"B48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-60327-323-7_7","article-title":"Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia.","volume":"617","author":"Negus","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMp1011512","article-title":"A flood of opioids, a rising tide of deaths.","volume":"363","author":"Okie","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00002826-199619010-00009","article-title":"Analgesic efficacy of the kappa-receptor agonist, enadoline, in dental surgery pain.","volume":"19","author":"Pande","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/ejp.1002","article-title":"The analgesic and anti-inflammatory effects of Salvinorin A analogue beta-tetrahydropyran Salvinorin B in mice.","volume":"21","author":"Paton","year":"2017","journal-title":"Eur. J. Pain"},{"key":"B52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors.","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"B53","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1096\/fasebj.27.1_supplement.1171.3","article-title":"Development of biased agonists at the kappa opioid receptor.","volume":"27","author":"Phillips","year":"2013","journal-title":"FASEB J."},{"key":"B54","first-page":"341","article-title":"Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.","volume":"230","author":"Porreca","year":"1984","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.lfs.2005.09.008","article-title":"Psychopharmacology of the hallucinogenic sage Salvia divinorum.","volume":"78","author":"Prisinzano","year":"2005","journal-title":"Life Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/bf02245945","article-title":"Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze.","volume":"118","author":"Privette","year":"1995","journal-title":"Psychopharmacology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","article-title":"Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans.","volume":"72","author":"Ranganathan","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"10464","DOI":"10.1021\/jm501521d","article-title":"Synthesis and kappa-opioid receptor activity of furan-substituted salvinorin A analogues.","volume":"57","author":"Riley","year":"2014","journal-title":"J. Med. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2016.06.029","article-title":"Opioid-induced hyperalgesia: cellular and molecular mechanisms.","volume":"338","author":"Roeckel","year":"2016","journal-title":"Neuroscience"},{"key":"B60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.phrs.2016.01.032","article-title":"The hallucinogenic diterpene salvinorin A inhibits leukotriene synthesis in experimental models of inflammation.","volume":"106","author":"Rossi","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.","volume":"99","author":"Roth","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010\u20132015.","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"key":"B64","doi-asserted-by":"publisher","first-page":"41595","DOI":"10.1074\/jbc.m112.381368","article-title":"Ligand directed signaling differences between rodent and human \u03ba-opioid receptors.","volume":"287","author":"Schattauer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B65","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF02244871","article-title":"Behavioural and pharmacological characterisation of the elevated \u201czero-maze\u201d as an animal model of anxiety.","volume":"116","author":"Shepherd","year":"1994","journal-title":"Psychopharmacology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1021\/acs.jmedchem.7b00148","article-title":"Addressing Structural Flexibility at the A-Ring on Salvinorin A: discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.","volume":"60","author":"Sherwood","year":"2017","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bph.12692","article-title":"Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.","volume":"172","author":"Simonson","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/s0306-4522(01)00333-5","article-title":"Naloxone fails to produce conditioned place aversion in mu-opioid receptor knock-out mice.","volume":"106","author":"Skoubis","year":"2001","journal-title":"Neuroscience"},{"key":"B69","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1254\/jjp.58.435","article-title":"The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference.","volume":"58","author":"Suzuki","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ejpb.2009.01.002","article-title":"Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.","volume":"72","author":"Teksin","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.pain.2010.12.036","article-title":"A population-based survey of chronic pain and its treatment with prescription drugs.","volume":"152","author":"Toblin","year":"2011","journal-title":"Pain"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1097\/j.pain.0000000000000641","article-title":"Health-related quality of life and burden of disease in chronic pain measured with the 15D instrument.","volume":"157","author":"Vartiainen","year":"2016","journal-title":"Pain"},{"key":"B73","first-page":"617","article-title":"The kappa opioid receptor agonist, U50,488, exacerbates conditioned fear in mice.","volume":"25","author":"Vunck","year":"2011","journal-title":"FASEB J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s002130100788","article-title":"Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.","volume":"157","author":"Walsh","year":"2001","journal-title":"Psychopharmacology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuropharm.2016.04.022","article-title":"kappa Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice.","volume":"110","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.","volume":"352","author":"White","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.2527\/1990.6841072x","article-title":"The effects of selected bulky substituents on the pulmonary toxicity of 3-furyl ketones in mice.","volume":"68","author":"Wilson","year":"1990","journal-title":"J. Anim. Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/bph.13474","article-title":"The G-protein biased partial kappa opioid receptor agonist 6\u2019-GNTI blocks hippocampal paroxysmal discharges without inducing aversion.","volume":"173","author":"Zangrandi","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/aps.2014.145","article-title":"Novel kappa-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation.","volume":"36","author":"Zhang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"B80","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00213-004-2087-0","article-title":"Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.","volume":"179","author":"Zhang","year":"2005","journal-title":"Psychopharmacology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","article-title":"Development of functionally selective, small molecule agonists at kappa opioid receptors.","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:41:44Z","timestamp":1667497304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":81,"alternative-id":["10.3389\/fnins.2020.00765"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2020.00765","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]},"article-number":"765"}}